Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.397
S. Wadhwa, E. Higginbotham
Glaucoma is disease of the optic nerve, which, if left untreated, can lead to irreversible loss of vision. Over the past few decades there have been significant advances in both the medical and surgical treatment of glaucoma. Today, with early diagnosis and treatment, most patients with glaucoma can be well controlled and avoid significant loss of vision from glaucoma. Since glaucoma is a common ophthalmologic disease, with high prevalence in the elderly, it is important to understand the various treatment options. The purpose of this review is to discuss the management and treatment of primary open-angle glaucoma (medical management and surgical options) and review the key studies that aid physicians in the management of this disease.
{"title":"Strategies to reduce the progression of glaucoma","authors":"S. Wadhwa, E. Higginbotham","doi":"10.2217/1745509X.3.3.397","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.397","url":null,"abstract":"Glaucoma is disease of the optic nerve, which, if left untreated, can lead to irreversible loss of vision. Over the past few decades there have been significant advances in both the medical and surgical treatment of glaucoma. Today, with early diagnosis and treatment, most patients with glaucoma can be well controlled and avoid significant loss of vision from glaucoma. Since glaucoma is a common ophthalmologic disease, with high prevalence in the elderly, it is important to understand the various treatment options. The purpose of this review is to discuss the management and treatment of primary open-angle glaucoma (medical management and surgical options) and review the key studies that aid physicians in the management of this disease.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"9 1","pages":"397-403"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.397","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.349
P. Vestergaard
Evaluation of: Richards JB, Papaioannou A, Adachi JD et al.: Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med. 167, 188–194 (2007) [1]. The results of a cohort study of 5008 community-dwelling subjects aged over 50 years was presented. Among these, 137 were daily users of selective serotonin-reuptake inhibitors. The study reported an increased risk of fragility fractures (fractures occurring after minimal trauma; hazard ratio: 2.1; 95% confidence interval: 1.3–3.4) and an increased risk of falls (hazard ratio: 2.2; 95% confidence interval: 1.4–3.5) among daily users of selective serotonin-reuptake inhibitors. Bone mineral density was lower in the hip in daily selective serotonin-reuptake inhibitors users and there was a trend towards lower bone mineral density in the spine. A dose–response relationship was present.
Richards JB, Papaioannou A, Adachi JD等:选择性血清素再摄取抑制剂对骨折风险的影响。拱门。实习生。中华医学杂志，2004,18(5):344 - 344。对5008名年龄在50岁以上的社区居民进行了队列研究。其中，137人每天服用选择性血清素再摄取抑制剂。该研究报告了脆性骨折的风险增加(骨折发生在最小创伤后;风险比:2.1;95%置信区间:1.3-3.4)和跌倒风险增加(风险比:2.2;95%置信区间:1.4-3.5)在选择性血清素再摄取抑制剂的日常使用者中。每天使用选择性血清素再摄取抑制剂的患者髋部骨密度较低，脊柱骨密度也有降低的趋势。存在剂量-反应关系。
{"title":"Effect of selective serotonin-reuptake inhibitors on the risk of fracture","authors":"P. Vestergaard","doi":"10.2217/1745509X.3.3.349","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.349","url":null,"abstract":"Evaluation of: Richards JB, Papaioannou A, Adachi JD et al.: Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med. 167, 188–194 (2007) [1]. The results of a cohort study of 5008 community-dwelling subjects aged over 50 years was presented. Among these, 137 were daily users of selective serotonin-reuptake inhibitors. The study reported an increased risk of fragility fractures (fractures occurring after minimal trauma; hazard ratio: 2.1; 95% confidence interval: 1.3–3.4) and an increased risk of falls (hazard ratio: 2.2; 95% confidence interval: 1.4–3.5) among daily users of selective serotonin-reuptake inhibitors. Bone mineral density was lower in the hip in daily selective serotonin-reuptake inhibitors users and there was a trend towards lower bone mineral density in the spine. A dose–response relationship was present.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"5 4 1","pages":"349-350"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.349","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.309
H. Lavretsky, Michael R. Irwin
This article summarizes the literature on resilience to stress and aging. Key concepts and definitions of resilience are identified, and psychosocial and biological factors contributing to resilience that are universal across ages, as well as those that are unique to aging, are reviewed. Current and potentially useful intervention approaches to promote resilience and wellbeing are also reviewed. Views on future directions in resilience research and interventions targeting resilience are offered.
{"title":"Resilience and aging","authors":"H. Lavretsky, Michael R. Irwin","doi":"10.2217/1745509X.3.3.309","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.309","url":null,"abstract":"This article summarizes the literature on resilience to stress and aging. Key concepts and definitions of resilience are identified, and psychosocial and biological factors contributing to resilience that are universal across ages, as well as those that are unique to aging, are reviewed. Current and potentially useful intervention approaches to promote resilience and wellbeing are also reviewed. Views on future directions in resilience research and interventions targeting resilience are offered.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"309-323"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.333
R. Kane
Chronic illness is the predominant disease pattern today; however, healthcare systems have been slow to adapt. This paper describes a number of strategies to enhance chronic illness care, now often termed ‘care for long-term conditions’, including targeting, prior authorization, guidelines, profiling, financial incentives, gatekeeping, subcapitation, case management, information systems, interdisciplinary teams and end-of-life care. It compares how such programs have been implemented in the UK, under the NHS framework, and in the USA.
{"title":"Strategies for improving chronic illness care: some issues for the NHS","authors":"R. Kane","doi":"10.2217/1745509X.3.3.333","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.333","url":null,"abstract":"Chronic illness is the predominant disease pattern today; however, healthcare systems have been slow to adapt. This paper describes a number of strategies to enhance chronic illness care, now often termed ‘care for long-term conditions’, including targeting, prior authorization, guidelines, profiling, financial incentives, gatekeeping, subcapitation, case management, information systems, interdisciplinary teams and end-of-life care. It compares how such programs have been implemented in the UK, under the NHS framework, and in the USA.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"333-342"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.361
A. Tiehuis, E. Berg, L. Kappelle, G. Biessels
This review addresses the impact of Type 2 diabetes mellitus on the brain. We show that there is convincing evidence that Type 2 diabetes mellitus is associated with accelerated cognitive decline and dementia. The structural basis for these cognitive deficits includes both vascular lesions and global cerebral atrophy. Cerebral changes may already develop in prediabetes mellitus stages. Several areas of uncertainty need to be resolved in order to develop effective preventive strategies. Information on the risk factors for accelerated cognitive decline in patients with Type 2 diabetes mellitus is still scarce. Identification of these factors might help to identify individuals who are at risk for clinically relevant impairments and to develop specific interventions. Further studies on the course of development of cognitive decline in Type 2 diabetes mellitus may help to decide at what stage these interventions should be initiated.
{"title":"Cognition and dementia in Type 2 diabetes: brain imaging correlates and metabolic and vascular risk factors","authors":"A. Tiehuis, E. Berg, L. Kappelle, G. Biessels","doi":"10.2217/1745509X.3.3.361","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.361","url":null,"abstract":"This review addresses the impact of Type 2 diabetes mellitus on the brain. We show that there is convincing evidence that Type 2 diabetes mellitus is associated with accelerated cognitive decline and dementia. The structural basis for these cognitive deficits includes both vascular lesions and global cerebral atrophy. Cerebral changes may already develop in prediabetes mellitus stages. Several areas of uncertainty need to be resolved in order to develop effective preventive strategies. Information on the risk factors for accelerated cognitive decline in patients with Type 2 diabetes mellitus is still scarce. Identification of these factors might help to identify individuals who are at risk for clinically relevant impairments and to develop specific interventions. Further studies on the course of development of cognitive decline in Type 2 diabetes mellitus may help to decide at what stage these interventions should be initiated.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"361-373"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.361","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68186902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.287
D. Bourla, S. Schwartz
Age-related macular degeneration causes blindness in elderly individuals. In the last decade, the search for mechanisms that initiate and sustain neovascularization in age-related macular degeneration has focused on the actions of vascular endothelial growth factor. The first approved drug that inhibited vascular endothelial growth factor for the treatment of neovascular age-related macular degeneration was pegaptanib sodium. This pegylated RNA aptamer has shown efficacy in two pivotal Phase III trials for the treatment of neovascular age-related macular degeneration. Pegaptanib therefore has the notable distinction of being the only aptamer therapeutic approved for use in humans, possibly paving the road for future aptamer applications.
{"title":"Pegaptanib: vascular endothelial growth factor inhibition in age-related macular degeneration","authors":"D. Bourla, S. Schwartz","doi":"10.2217/1745509X.3.3.287","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.287","url":null,"abstract":"Age-related macular degeneration causes blindness in elderly individuals. In the last decade, the search for mechanisms that initiate and sustain neovascularization in age-related macular degeneration has focused on the actions of vascular endothelial growth factor. The first approved drug that inhibited vascular endothelial growth factor for the treatment of neovascular age-related macular degeneration was pegaptanib sodium. This pegylated RNA aptamer has shown efficacy in two pivotal Phase III trials for the treatment of neovascular age-related macular degeneration. Pegaptanib therefore has the notable distinction of being the only aptamer therapeutic approved for use in humans, possibly paving the road for future aptamer applications.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"287-294"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.287","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.295
D. Fenig, A. Mccullough
Erectile dysfunction affects more than 150 million men worldwide and is increasingly prevalent. Elderly men are at increased risk for erectile dysfunction, which is, in part, owing to medical comorbidities associated with erectile dysfunction. Sildenafil, the first US FDA-approved, oral phosphodiesterase type-5 inhibitor, has revolutionized the treatment of erectile dysfunction since its approval in 1998. High treatment success rates and low number of adverse events, in addition to significant improvements in psychosocial parameters, have resulted in increased patient and physician satisfaction with sildenafil, and increased usage. Safety has been demonstrated in patients with stable cardiovascular disease, and rates of discontinuation owing to adverse effects remains low.
{"title":"Sildenafil in the treatment of erectile dysfunction","authors":"D. Fenig, A. Mccullough","doi":"10.2217/1745509X.3.3.295","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.295","url":null,"abstract":"Erectile dysfunction affects more than 150 million men worldwide and is increasingly prevalent. Elderly men are at increased risk for erectile dysfunction, which is, in part, owing to medical comorbidities associated with erectile dysfunction. Sildenafil, the first US FDA-approved, oral phosphodiesterase type-5 inhibitor, has revolutionized the treatment of erectile dysfunction since its approval in 1998. High treatment success rates and low number of adverse events, in addition to significant improvements in psychosocial parameters, have resulted in increased patient and physician satisfaction with sildenafil, and increased usage. Safety has been demonstrated in patients with stable cardiovascular disease, and rates of discontinuation owing to adverse effects remains low.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"295-303"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.295","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.275
M. Shapira, P. Tsirigotis, I. Resnick, R. Or
MY Shapira†, P Tsirigotis, IB Resnick & R Or †Author for correspondence Hadassah–Hebrew University, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Medical Center, PO Box 12000, Jerusalem 91120, Israel Tel.: +972 2677 8351; Fax: +972 2641 0876; E-mail: shapiram@ hadassah.org.il “Age is one of the most significant factors that adversely affects the outcome of bone marrow or blood stem cell transplantation”
MY Shapira†，P Tsirigotis, IB Resnick & R Or†通讯作者哈达萨-希伯来大学，骨髓移植和癌症免疫治疗系，医疗中心，邮政信箱12000，耶路撒冷91120，以色列电话:+972 2677 8351;传真:+972 2641 0876;“年龄是影响骨髓或血液干细胞移植结果的最重要因素之一。”
{"title":"Allogeneic bone marrow transplantation in the elderly: an emerging change in the transplantation field","authors":"M. Shapira, P. Tsirigotis, I. Resnick, R. Or","doi":"10.2217/1745509X.3.3.275","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.275","url":null,"abstract":"MY Shapira†, P Tsirigotis, IB Resnick & R Or †Author for correspondence Hadassah–Hebrew University, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Medical Center, PO Box 12000, Jerusalem 91120, Israel Tel.: +972 2677 8351; Fax: +972 2641 0876; E-mail: shapiram@ hadassah.org.il “Age is one of the most significant factors that adversely affects the outcome of bone marrow or blood stem cell transplantation”","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"275-277"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.275","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-06-11DOI: 10.2217/1745509X.3.3.305
H. Zetterberg, U. Andreasson
Every other year, Abraham Fisher of the Israel Institute for Biological Research in Ness-Ziona (Israel) and Israel Hanin of Loyola University, Maywood (IL, USA), join forces with two European scientists to host a conference on two of our most common neurodegenerative diseases: Alzheimer’s disease (AD) and Parkinson’s disease (PD). This year, the meeting was held in Salzburg, Austria, and the local hosts were Werner Poewe, who chairs the department of neurology at the Medical University of Innsbruck (Austria), and Manfred Windisch, who heads the Austrian research organization JSW-Research Ltd in Graz (Austria). The program attracted 2150 participants from 59 different countries, which is a record in the history of the AD/PD meetings. A distinctive goal of the AD/PD meetings is to provide a forum for the presentation of results focused on AD and PD individually, while also covering the latest developments regarding the commonalities between neurodegenerative diseases in general. The reason for the latter focus is becoming more and more apparent. AD and PD share certain clinical, pathological and biochemical features. Both are prevalent, age-related neurodegenerative diseases that are characterized by premature neuronal death and protein aggregation caused by genetic and environmental factors in a complex interaction, and both pose an enormous threat to public health resources, especially in the light of the increased life expectancy worldwide. The currently available treatments for AD and PD are focused on replacing the neurotransmitter that is missing: acetylcholine in AD and dopamine in PD. In both diseases, however, substantial efforts have been made to translate the advances on understanding the molecular pathogenesis, especially the importance of protein aggregation, into therapeutic strategies. This conference report provides an overview of the major recent developments in the complex spectrum of AD, PD and some other related disorders as reflected in the meeting.
{"title":"Update on Alzheimer’s and Parkinson’s diseases","authors":"H. Zetterberg, U. Andreasson","doi":"10.2217/1745509X.3.3.305","DOIUrl":"https://doi.org/10.2217/1745509X.3.3.305","url":null,"abstract":"Every other year, Abraham Fisher of the Israel Institute for Biological Research in Ness-Ziona (Israel) and Israel Hanin of Loyola University, Maywood (IL, USA), join forces with two European scientists to host a conference on two of our most common neurodegenerative diseases: Alzheimer’s disease (AD) and Parkinson’s disease (PD). This year, the meeting was held in Salzburg, Austria, and the local hosts were Werner Poewe, who chairs the department of neurology at the Medical University of Innsbruck (Austria), and Manfred Windisch, who heads the Austrian research organization JSW-Research Ltd in Graz (Austria). The program attracted 2150 participants from 59 different countries, which is a record in the history of the AD/PD meetings. A distinctive goal of the AD/PD meetings is to provide a forum for the presentation of results focused on AD and PD individually, while also covering the latest developments regarding the commonalities between neurodegenerative diseases in general. The reason for the latter focus is becoming more and more apparent. AD and PD share certain clinical, pathological and biochemical features. Both are prevalent, age-related neurodegenerative diseases that are characterized by premature neuronal death and protein aggregation caused by genetic and environmental factors in a complex interaction, and both pose an enormous threat to public health resources, especially in the light of the increased life expectancy worldwide. The currently available treatments for AD and PD are focused on replacing the neurotransmitter that is missing: acetylcholine in AD and dopamine in PD. In both diseases, however, substantial efforts have been made to translate the advances on understanding the molecular pathogenesis, especially the importance of protein aggregation, into therapeutic strategies. This conference report provides an overview of the major recent developments in the complex spectrum of AD, PD and some other related disorders as reflected in the meeting.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"305-307"},"PeriodicalIF":0.0,"publicationDate":"2007-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.3.305","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-03-28DOI: 10.2217/1745509X.3.2.135
C. Weber, G. Zulian
Is chemotherapy underutilized in the elderly? Yes, most probably. Back in 1990, a group of pioneers in the field of geriatric oncology published a provocative editorial entitled ‘Why are elderly cancer patients badly treated?’ [1]. Eminent members of the same group recently concluded their scientific review on the treatment of cancer in older patients by writing: “Although we are on the right track, there is still a long way to go” [2]. Answers have thus been provided in the interval between these two communications but many questions still remain. There have been remarkable societal changes in the 20th century and the unexpected lengthening of life-expectancy has been one of the most crucial. Previously, the third and the fourth age were the privilege of few lucky individuals, capable of escaping from misery, epidemics and catastrophes. Today, the vast majority of us may expect to get old and to live these years in very good health. However, parallel to the aging of the population, cancer disorders have increased in number and over half are now diagnosed in the eight, ninth and tenth decades of life. If the incidence of cancer is 207/100,000 below 65 years of age, it rises to 2261/100,000 above that age, that is, 11-fold higher [3]. In other words, cancer has now become a disease of the elderly. It is predicted that 15 million new cases of cancer will be diagnosed worldwide in the year 2020 in comparison with 10 million 20 years before [4]. And the evidence is that the majority will concern people over the age of 70 years, the senior adults. These numbers demand serious analysis. What we have learned over the past years should be used to prepare for the future in the full respect of the ethics of our societies. To find the balance between autonomy, beneficence and justice is a major challenge. Despite scientific advances in the
{"title":"Is chemotherapy underutilized in the elderly","authors":"C. Weber, G. Zulian","doi":"10.2217/1745509X.3.2.135","DOIUrl":"https://doi.org/10.2217/1745509X.3.2.135","url":null,"abstract":"Is chemotherapy underutilized in the elderly? Yes, most probably. Back in 1990, a group of pioneers in the field of geriatric oncology published a provocative editorial entitled ‘Why are elderly cancer patients badly treated?’ [1]. Eminent members of the same group recently concluded their scientific review on the treatment of cancer in older patients by writing: “Although we are on the right track, there is still a long way to go” [2]. Answers have thus been provided in the interval between these two communications but many questions still remain. There have been remarkable societal changes in the 20th century and the unexpected lengthening of life-expectancy has been one of the most crucial. Previously, the third and the fourth age were the privilege of few lucky individuals, capable of escaping from misery, epidemics and catastrophes. Today, the vast majority of us may expect to get old and to live these years in very good health. However, parallel to the aging of the population, cancer disorders have increased in number and over half are now diagnosed in the eight, ninth and tenth decades of life. If the incidence of cancer is 207/100,000 below 65 years of age, it rises to 2261/100,000 above that age, that is, 11-fold higher [3]. In other words, cancer has now become a disease of the elderly. It is predicted that 15 million new cases of cancer will be diagnosed worldwide in the year 2020 in comparison with 10 million 20 years before [4]. And the evidence is that the majority will concern people over the age of 70 years, the senior adults. These numbers demand serious analysis. What we have learned over the past years should be used to prepare for the future in the full respect of the ethics of our societies. To find the balance between autonomy, beneficence and justice is a major challenge. Despite scientific advances in the","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"135-137"},"PeriodicalIF":0.0,"publicationDate":"2007-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.2.135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68186552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：